COMMUNIQUÉS West-GlobeNewswire

-
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
07/07/2025 -
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
07/07/2025 -
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
07/07/2025 -
Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries
07/07/2025 -
Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment
07/07/2025 -
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
07/07/2025 -
SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board
07/07/2025 -
Synfini Adds $8.9 Million Discovery Funding to Speed Small Molecule Drug Development
07/07/2025 -
Nudj Health Appoints Dr. Padmaja Patel as Chief Medical Officer to Advance Lifestyle Medicine Services
07/07/2025 -
First patient dosed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy
07/07/2025 -
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
07/07/2025 -
CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT
07/07/2025 -
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER
07/07/2025 -
ONWARD Medical Adds Entrepreneur and Neurotechnology Thought Leader Tim Denison, PhD to its Board of Directors
07/07/2025 -
Eleva administers first dose of its Factor H biological treatment in C3-Glomerulopathy to healthy volunteers
07/07/2025 -
Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe
07/07/2025 -
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
07/07/2025 -
Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo®) for Skin Health
07/07/2025 -
Spectral Medical Inc. Announces Filing of Base Shelf Prospectus
04/07/2025
Pages